profit from every $100 of sales.
$0$100
Veradermics
$156.56+5.47% today
+306.9% since Feb 2, 26
1-year low $37.031-year high $156.56
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Veradermics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2023 to $0 in 2025, with -$70.0 million of profit last year.
SalesProfit
Veradermics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Veradermics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Veradermics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 0 | 0 | 0 | |
| – | – | – | |
| -17 | -26 | -72 | |
| -16 | -26 | -70 | |
| -16 | -26 | -70 | |
| -1.51 | -1.37 | -2.00 | |
| – | – | – | |
| – | – | – | |
| – | – | – |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 18 | 56 | 153 |
| Cash | 16 | 53 | 22 |
| Total debt | 1 | 0 | 0 |
| Total liabilities | 40 | 104 | 274 |
| -22 | -48 | -121 | |
| 14 | 20 | 35 | |
| – | – | – | |
| 74.1% | 54.6% | 57.8% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -14 | -24 | -72 | |
| – | 0 | 0 | |
| -14 | -24 | -72 | |
| Dividends paid | – | – | – |
| – | – | – | |
| 0 | 0 | 1 |
Valuation
- –
- –
- –
- -44.7×
- –
- –
- –
- -1.1%
- -1.1%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -15.0%
- -32.6%
- -95.4%
- -13.7%
- -15.0%
- –
Growth
- –
- –
- −202.4%
- –
- +59.4%
Financial health
- -2.9×
- -0.00
- 0.0%
- -71.4×
- 16.66
- 59.12
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 958
Bottom 21%of 888
Bottom 31%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -1.32 | -0.56 | −135.7% |
| Mar 30, 2026 | -0.76 | -1.81 | +58.1% |
| Feb 25, 2026 | -1.63 | -1.81 | +10.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
43No pass
Philip Fisher
35No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
32No pass
Questions about Veradermics
Is Veradermics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Veradermics AI analysis
What does Veradermics do?
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. It is in Biotechnology, based in New Haven, CT, United States, with 24 employees.
Does Veradermics pay a dividend?
No. Veradermics does not pay a dividend at the moment.
Is Veradermics stock halal?
Yes. Veradermics passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
Who are Veradermics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Veradermics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.